GDF15 and Related Biomarkers Open access Peer reviewed

Machine learning and plasma growth differentiation factor-15 (GDF15) for early risk stratification of heart failure progression in a long-latency doxorubicin cardiomyopathy model

Kaui P. Lebarbenchon, Anjali Kumar, Brian Ladle, Christopher B. Douville and 1 more

Cardio-Oncology | Jun 25, 2026

Scollr summary

What this paper is about

These findings support further study of multi-parameter early monitoring and predictive modeling for risk stratification of accelerated cardiotoxic progression in animal models and, ultimately, in appropriately validated clinical cohorts.

Full abstract

Read the full abstract

BACKGROUND: Anthracycline-induced cardiotoxicity is a major cause of late heart failure (HF) in cancer survivors. Yet early identification of individuals at risk for accelerated cardiotoxic progression remains a clinical challenge. This study leveraged a rat model of long-latency doxorubicin cardiotoxicity to identify early features associated with progression to a prespecified 7-month HF endpoint and to develop a machine learning risk-stratification framework. METHODS: Doxorubicin-treated rats (both sexes, n = 32 doxorubicin treated and n = 22 saline) were monitored with monthly echocardiography and monthly plasma concentrations of growth differentiation factor-15 (GDF15) for up to 12 months. We defined the primary HF endpoint as the occurrence of severe systolic dysfunction (fractional shortening (FS) < 30%) by 7 months post-chemotherapy. A Logistic Regression (LR) model was compared to Random Forest (RF) and XGBoost (XGB) classifiers in distinguishing animals that reached this endpoint by 7 months from those with delayed or absent progression within that time frame. Model performance was evaluated by area under the ROC curve (AUC), Brier score, calibration plots, decision curve analysis (DCA), and DeLong tests for AUC differences. Feature importance was examined via permutation testing, SHapley Additive exPlanations (SHAP) values, and accumulated local effects (ALE) plots. RESULTS: Using 1,000 repeated stratified 60/40 train-validation splits, models were retrained and evaluated on the corresponding held-out validation subsets. LR achieved a median AUC of 0.81, RF 0.97, and XGB 0.93. Pairwise DeLong tests were not statistically significant, so the numerically higher AUCs for RF and XGB should be interpreted as suggestive rather than definitive evidence of superior discrimination. The machine learning models showed lower Brier scores (approximately 0.06 vs. 0.12 for logistic regression) and higher estimated net benefit in decision-curve analysis within this dataset. A label-permutation test indicated that RF performance exceeded chance (p < 0.05). Risk groups defined by machine learning-predicted probability showed strong time-to-HF separation on Kaplan-Meier analysis (log-rank p < 0.0001). DISCUSSION: Key predictors included early elevation in plasma GDF15 levels, early decline in FS (ΔFS), body weight, and sex. In this doxorubicin cardiotoxicity animal model, RF and XGB showed numerically higher discrimination than logistic regression, while sensitivity analyses indicated that GDF15 and ΔFS retained predictive signal beyond sex alone. CONCLUSION: These findings support further study of multi-parameter early monitoring and predictive modeling for risk stratification of accelerated cardiotoxic progression in animal models and, ultimately, in appropriately validated clinical cohorts.

Direct answer

What can I do from this paper page?

Use this page to scan "Machine learning and plasma growth differentiation factor-15 (GDF15) for early risk stratification of heart failure progression in a long-latency doxorubicin cardiomyopathy model" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow GDF15 and Related Biomarkers research, save the paper, or map adjacent work.

Authors

Researchers on this paper

Kaui P. Lebarbenchon

first | Johns Hopkins University | ORCID 0000-0002-7096-6308

Anjali Kumar

middle | Johns Hopkins University

Brian Ladle

middle | Johns Hopkins University

Christopher B. Douville

middle | Johns Hopkins University

Kathy Gabrielson

last | Johns Hopkins University

Research areas

Follow related topics

Citation

BibTeX

@article{Lebarbenchon2026Machine,
  title = {Machine learning and plasma growth differentiation factor-15 (GDF15) for early risk stratification of heart failure progression in a long-latency doxorubicin cardiomyopathy model},
  author = {Kaui P. Lebarbenchon and Anjali Kumar and Brian Ladle and Christopher B. Douville and Kathy Gabrielson},
  journal = {Cardio-Oncology},
  year = {2026},
  doi = {10.1186/s40959-026-00523-w},
  url = {https://doi.org/10.1186/s40959-026-00523-w}
}

FAQ

Using this paper in a discovery workflow

How do I find related work for this paper?

Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.

How can I keep up with new GDF15 and Related Biomarkers research papers?

Follow GDF15 and Related Biomarkers research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.

Can I cite this paper from this page?

This page includes a static BibTeX block for Machine learning and plasma growth differentiation factor-15 (GDF15) for early risk stratification of heart failure progression in a long-latency doxorubicin cardiomyopathy model. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.

Follow this research in Scollr

Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.

Get the app